RxDoctor Payments Data

James Barry, MD

Neurology · Bedford, TXNPI 1952304743

Payments from drug & device makers

$117,912in general payments, 2019–2025

Across 2,034 payments — averaging $57.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$27K
  • Sanofi$26K
  • Biogen$18K
  • Genentech USA, Inc.$10K
  • Bristol Myers Squibb$7K
  • AbbVie$4K
  • plus $27K from 54 others

What the payments were for

  • Consulting fees$17,93320%
  • Speaking & faculty fees$38,09742%
  • Travel & lodging$2,0412%
  • Food & beverage$33,01836%
  • Education$1960%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.9$26,628
Sanofi56$25,873
Biogen136$17,915
Genentech USA, Inc.62$9,537
Bristol Myers Squibb32$7,168
AbbVie(2 entities)229$3,603
Banner Life Sciences, LLC12$3,561
Novartis130$1,904
EMD Serono, Inc.179$1,710
Teva Pharmaceuticals USA, Inc.244$1,634
Grifols USA, LLC67$1,371
Amgen(2 entities)62$1,270
Acadia Pharmaceuticals Inc72$1,144
UCB, Inc.47$1,023
AstraZeneca(2 entities)53$942
TG Therapeutics, Inc.23$653
Neurocrine Biosciences, Inc.27$630
CSL Behring29$610
Pfizer37$608
Amneal Pharmaceuticals LLC38$604
Lilly USA, LLC30$581
SK Life Science, Inc.30$499
Alnylam Pharmaceuticals Inc.24$471
Eisai Inc.17$411
Merz Pharmaceuticals, LLC13$399
Tanabe Pharma America, Inc.23$359
Biohaven Pharmaceutical Holding Company Ltd.16$308
Jazz Pharmaceuticals Inc.11$303
Johnson & Johnson19$297
MDD US Operations, LLC15$283
Argenx US, Inc.14$281
GE HealthCare16$280
Sunovion Pharmaceuticals Inc.18$275
Biohaven Pharmaceuticals, Inc.14$264
Lundbeck LLC15$239
Impel Pharmaceuticals Inc.14$237
Vanda Pharmaceuticals Inc.7$219
Boston Scientific9$216
Upsher-smith Laboratories LLC13$213
Kyowa Kirin, Inc.11$211
Acorda Therapeutics, Inc7$211
Merz North America, Inc.8$205
Ipsen Biopharmaceuticals, Inc10$200
ANI Pharmaceuticals, Inc.10$190
Scilex Pharmaceuticals Inc.9$171
Harmony Biosciences LLC2$158
Octapharma USA, Inc.8$157
E.r. Squibb & Sons, L.L.C.12$155
Adamas Pharmaceuticals, Inc.10$154
Supernus Pharmaceuticals, Inc.8$139
Mallinckrodt Enterprises LLC8$127
Avanir Pharmaceuticals, Inc.6$101
Revance Therapeutics, Inc.2$100
Axsome Therapeutics, Inc.4$86
Takeda Pharmaceuticals U.S.A., Inc.4$82
Amylyx Pharmaceuticals, Inc.3$81
Mallinckrodt Hospital Products Inc.3$75
Arbor Pharmaceuticals, Inc.4$58
Azurity Pharmaceuticals, Inc.4$58
Bausch Health US, LLC3$56

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$117,912 in reported general payments places this provider in the 85th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$3,450,485
Medicare patients
920
Services billed
97,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4652$511,429
NuplazidPimavanserin Tartrate33$172,710
NuedextaDextromethorphan Hbr/Quinidine12$37,310
Emgality PenGalcanezumab-Gnlm32$29,214
Dalfampridine ErDalfampridine49$27,155
Nurtec OdtRimegepant Sulfate13$14,247
UbrelvyUbrogepant11$12,601
NayzilamMidazolam11$7,201
Donepezil Hcl924$6,754
Memantine Hcl425$6,106
Gabapentin262$5,753
Lacosamide61$4,711
Baclofen143$4,484
Levetiracetam134$3,647
Rivastigmine13$2,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$1,371$511,42952 claims
Acadia Pharmaceuticals IncNuplazid$1,144$172,71033 claims
Avanir Pharmaceuticals, Inc.Nuedexta$101$37,31012 claims
PfizerNurtec Odt$608$14,24713 claims
AbbVieUbrelvy$3,603$12,60111 claims
UCB, Inc.Nayzilam$1,023$7,20111 claims
Upsher-smith Laboratories LLCTopiramate$213$78949 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,246 neurology providers in Texas.

Other neurology in Bedford

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →